New mRNA vaccine aims to shield seniors from RSV
NCT ID NCT07128121
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new mRNA vaccine called IN006 against respiratory syncytial virus (RSV) in 500 healthy adults aged 60 and older. The vaccine is given as two different doses, with a booster after 12 or 24 months. Researchers will monitor safety and measure immune responses like antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Respiratory syncytial virus IN006 bivalent mRNA vaccine
- What this could lead to
- If successful, this could lead to a new vaccine option to protect older adults from severe RSV disease.
- What could go wrong
- This is an early phase 2 trial with only 500 participants, so results may not confirm effectiveness or safety in larger populations. Side effects are possible, and the vaccine may not provide lasting protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.